Kerecis Showcases Fish-Skin Graft Data at SAWC Spring

New clinical trial shows superior effectiveness of intact fish-skin grafts for treating severe pressure ulcers.

Apr. 8, 2026 at 6:20am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph of a severe pressure ulcer, with the damaged tissue and internal structures visible as ghostly, glowing lines against a dark background, conveying the medical complexity and gravity of this condition.A new clinical trial shows the superior effectiveness of Kerecis' fish-skin grafts in treating severe, hard-to-heal pressure ulcers.Charlotte Today

Kerecis, a company pioneering the use of sustainably sourced fish-skin in cellular therapy and tissue regeneration, will present new clinical data on the effectiveness of its intact fish-skin grafts for treating severe pressure ulcers at the Symposium on Advanced Wound Care (SAWC) Spring 2026 in Charlotte, North Carolina. The real-world trial found that intact fish-skin demonstrated superior clinical effectiveness when compared with standard care for treating severe, hard-to-heal Stage 3 and 4 pressure ulcers.

Why it matters

Stage 3 and 4 pressure ulcers represent a major burden to patients and the healthcare system. Demonstrating the statistical superiority of intact fish-skin grafts in this complex patient population underscores the vital medical necessity of advanced biologic therapies when standard treatments stall.

The details

The industry-supported symposium will feature clinical insights on real-world applications of fish-skin grafts across complex and atypical wounds, as well as the presentation of the new clinical research. The real-world trial evaluated 80 patients, finding that ulcers treated with intact fish-skin achieved a 49% average percent area reduction, compared to a 34% reduction in the standard of care control group (p=0.0028). Additionally, 67.5% of wounds treated with intact fish-skin were categorized as either "Healed" or "Improved," significantly outpacing the 55.0% success rate observed in the control group (p=0.0379).

  • The industry-supported symposium will take place on Thursday, April 9, 2026, from 4:30 PM to 5:30 PM EDT.
  • The poster reception featuring 13 abstracts on intact fish-skin technology will be held on Friday, April 10, 2026, from 7:30 PM to 8:30 PM EDT.

The players

Kerecis

A company pioneering the use of sustainably sourced fish-skin in cellular therapy and tissue regeneration.

Dr. Anamika Agrawal

A clinician who will present insights on real-world applications of fish-skin grafts.

Dr. John C. Lantis II

A clinician who will present insights on real-world applications of fish-skin grafts and the new clinical research.

Carrie McGroarty, PA-C, MPAS, EdD

A clinician who will present insights on real-world applications of fish-skin grafts.

Fertram Sigurjonsson

The Kerecis Inventor & Founder and Coloplast Executive Vice President.

Got photos? Submit your photos here. ›

What they’re saying

“These findings provide crucial, real-world validation for the clinical and economic value of the Kerecis intact fish-skin technology.”

— Fertram Sigurjonsson, Coloplast Executive Vice President and Kerecis Inventor & Founder

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.